Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 19 Nov 2013 |
| 150,000 Orion A-shares converted into B-shares | 25 Oct 2013 |
| Orion Group Interim Report January-September 2013 | 22 Oct 2013 |
| Composition of the Nomination Committee of Orion Corporation | 22 Oct 2013 |
| Orion and Hospira have signed a license agreement to continue the collaboration with Precedex® | 21 Oct 2013 |